$35.26 Million in Sales Expected for Endologix, Inc. (NASDAQ:ELGX) This Quarter
Wall Street analysts expect Endologix, Inc. (NASDAQ:ELGX) to post $35.26 million in sales for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Endologix’s earnings, with the highest sales estimate coming in at $35.58 million and the lowest estimate coming in at $35.00 million. Endologix posted sales of $34.76 million in the same quarter last year, which suggests a positive year-over-year growth rate of 1.4%. The firm is expected to announce its next earnings report on Thursday, November 7th.
On average, analysts expect that Endologix will report full year sales of $142.70 million for the current year, with estimates ranging from $142.10 million to $143.85 million. For the next financial year, analysts expect that the company will report sales of $150.91 million, with estimates ranging from $150.00 million to $152.07 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Endologix.
Endologix (NASDAQ:ELGX) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.43. Endologix had a negative return on equity of 120.57% and a negative net margin of 60.32%. The firm had revenue of $36.24 million during the quarter, compared to analysts’ expectations of $36.09 million.
Shares of NASDAQ:ELGX traded up $0.10 during trading on Friday, hitting $3.82. 87,729 shares of the company’s stock were exchanged, compared to its average volume of 230,143. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.53 and a quick ratio of 1.80. Endologix has a 52-week low of $3.22 and a 52-week high of $16.00. The business’s 50-day simple moving average is $4.16 and its 200 day simple moving average is $6.06. The company has a market cap of $63.93 million, a price-to-earnings ratio of -0.53 and a beta of 0.34.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ELGX. JPMorgan Chase & Co. grew its holdings in Endologix by 859.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 114,768 shares of the medical instruments supplier’s stock valued at $838,000 after buying an additional 102,807 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new position in Endologix during the 2nd quarter valued at approximately $214,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Endologix by 14.3% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 71,343 shares of the medical instruments supplier’s stock valued at $517,000 after purchasing an additional 8,936 shares during the last quarter. M&T Bank Corp bought a new stake in shares of Endologix in the 2nd quarter valued at approximately $102,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Endologix by 868.3% in the 2nd quarter. Renaissance Technologies LLC now owns 613,906 shares of the medical instruments supplier’s stock valued at $4,445,000 after purchasing an additional 550,506 shares during the last quarter. Institutional investors and hedge funds own 77.91% of the company’s stock.
Endologix Company Profile
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.
Further Reading: What does EPS mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.